BIO Europe Spring 2026

The conversations worth having right now are with pharma and biotech teams facing three specific problems: 1. Biology that's run out of building blocks - programs where the canonical amino acids have been optimised as far as they'll go, and the next leap requires chemistries nature never evolved. 2. Manufacturing of product that needs new-to-nature building blocks that doesn't scale - whether that's peptide synthesis generating tonnes of waste per kilogram of API, or ADC conjugation chemistry that produces a mess of variants regulators don't like. 3. Patent cliffs that need next-generation molecules - from never-possible-before, but also concrete improved versions with new IP, better stability, longer half-lives... Our platform addresses all three through one approach: genetic code expansion. It's not a hypothesis - it's backed by Jason Chin's 20+ years of research, a publication record that includes some of the most groundbreaking work in synthetic biology, and by proprietary technologies we've validated at commercial conditions in our own labs.